Drug intelligence / Profile preview

FD-003

Development stage: Preclinical
Lead developer: Drug Farm
Modality: Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules

Overview

FD-003 is a molecular glue degrader currently in the discovery phase of development by Chengdu FenDi Pharmaceutical (Fendi Pharma). It is being investigated for the treatment of non-small cell lung cancer (NSCLC). As a molecular glue, FD-003 is designed to stabilize the interaction between an E3 ubiquitin ligase and a specific target protein (neo-substrate), leading to the target's ubiquitination and subsequent degradation via the proteasome. The specific molecular target for this program has not yet been disclosed by the company.

Beyond the preview

Go deeper on FD-003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FD-003.

Explore the full profile